Methocarbamol

USDailyMed:Methocarbamol AU:B2 M03BA03(WHO)M03BA53(WHO)M03BA73(WHO) CA:OTCUK:POM(Prescription only)US:℞-only (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate 532-03-6Y 4107 6829 DB00423Y 3964Y 125OD7737X D00402Y CHEBI:6832N ChEMBL1201117N DTXSID6023286 Interactive image O=C(OCC(O)COc1ccccc1OC)N InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)YKey:GNXFOGHNGIVQEH-UHFFFAOYSA-NY Methocarbamol, sold under the brand nameRobaxinamong others, is a medication used for short-termmusculoskeletalpain.It may be used together with rest, physical therapy, andpain medication.I‍‍‍‍‍‍​​​‍​​​​​​t has limited use forrheumatoid arthritisandcerebral palsy.Effects generally begin within half an hour.It is taken by mouth orinjection into a vein. Common side effects include headaches, sleepiness, and dizziness.Serious side effects may includeanaphylaxis, liver problems, confusion, andseizures.Use is not recommended inpregnancyandbreastfeeding.Because of the risk of injury, skeletal muscle relaxants should generally be avoided in geriatric patients.Methocarbamol is a centrally actingmuscle relaxant.How it works is unclear, but it does not appear to affect muscles directly. Methocarbamol was developed in 1956 in the laboratories ofA. H. Robins(later acquired byPfizer). Studies were directed towards the development ofpropanediolderivatives which possessed muscle relaxant properties superior to those ofmephenesin, which had low potency and a short duration of action.It was approved for medical use in the United States in 1957.It is available as ageneric medication.In 2023, it was the 121st most commonly prescribed medication in the United States, with more than 5million prescriptions.Methocarbamol is available in afixed-dose combinationwith ibuprofen asmethocarbamol/ibuprofen(sold under the brand name Summit Ultra).